Skip to main content
. 2020 Dec 23;4:100079. doi: 10.1016/j.jtauto.2020.100079

Fig. 7.

Fig. 7

A-1396076 inhibits MHC Class II expression induced by intranasal OVA/LPS challenge in mice. Balb/c mice were sensitized with ovalbumin in alum adjuvant on day 0 and 7 and challenged intranasally with ovalbumin with or without LPS on days 14 and 16. On day 17 bronchoalveolar lavage was performed and cells were analyzed by flow cytometry using anti-CD11c APC, anti-CD80 PCP-Cy5.5, anti-CD86 PE, and anti-MHC Class II FITC antibodies to assess mature dendritic cells (CD11c ​+ ​MHC Class II hi). Mice were treated orally with 10 ​mg/kg A-1396076 twice a day beginning on day 13 prior to the intranasal challenge. A) A-1396076 inhibited the number of mature dendritic cells in mice challenged with either OVA alone (red) or OVA plus LPS (green). ∗ ​= ​p ​< ​0.05 vs. OVA and ^ ​= ​p ​< ​0.05 vs. OVA/LPS by one-way ANOVA with Dunnett’s post-test. (B) A-1396076 dose dependently inhibited CD86 and MHC II expression in mice challenged with OVA/LPS (n ​= ​10 per group; one experiment). ∗ ​= ​p ​< ​0.05 vs. OVA/LPS by one-way ANOVA with Dunnett’s post-test. All data is expressed at mean ​± ​SEM.